Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals Inc    REGN

News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

Pharma execs weigh in on possible changes under Trump

share with twitter share with LinkedIn share with facebook
share via e-mail
12/02/2016 | 12:36am CET
Saunders gives an interview on the floor of the NYSE

Top executives from large U.S. drugmakers on Thursday discussed for the first time possible changes for the industry under President-elect Donald Trump, and issues that have damaged the reputation of their industry.

Since he was elected, Trump, who has said he wants to repeal Obamacare and reform Medicare and Medicaid, has not addressed the sharp drug price increases that dominated the Presidential campaign.

Pharma companies are breathing a sigh of relief, but Trump could be more critical of drugmakers and their price increases than the industry expects, Allergan Inc (>> Allergan, Inc.) Chief Executive Brent Saunders said on Thursday.

Saunders, speaking at the annual Forbes Healthcare Summit in New York, predicted Trump could be a "more vicious tweeter" against the drug industry than his former Democratic rival Hillary Clinton had been during the campaign.

Clinton's tweets committing to a crackdown on exorbitant drug price increases weighed heavily on pharmaceutical shares since her first tweet in September 2015. Pharma shares jumped in the days after Trump's election as Clinton's proposed price controls fell off the table.

Saunders said Americans are rightly angry about price increases, and the industry needs to police itself or face government repercussions.

"I worry today that the pharmaceutical industry has a very false sense of security because of the Trump administration and a Republican-controlled Congress," Saunders said.

Regeneron Pharmaceuticals (>> Regeneron Pharmaceuticals Inc) CEO Len Schleifer, speaking on a panel at the Forbes conference, said the industry will be seen in a bad light as long as it maintains the common practise of taking twice yearly, often double-digit, price increases on widely-used medicines.

"We as an industry have used price increases to fill gaps in innovation," he said.

"You can't say 'I set the price based on the value of the drug' and then have these egregious price increases," Schleifer said, adding that the value of a drug to society does not increase each year.

Pfizer Inc (>> Pfizer Inc.) CEO Ian Read took exception to Schleifer's characterization of the price hikes, arguing the cost of prescription drugs as a percentage of overall healthcare spending had not changed in two decades.

In an overhauled U.S. healthcare plan under Trump, Read said he would like to see financial risk shift from insurers to providers, such as hospitals, with an emphasis on prevention and wellness.

"Give them the tools and the freedom and the incentive to manage that risk," Read said.

Separately, Merck & Co (>> Merck & Co., Inc.) CEO Ken Frazier said he thought one of Trump's proposed healthcare reform policies - allowing the import of cheaper drugs from other countries - will not work. The U.S. pays more than any other country for medicines, and current U.S. law forbids importation of drugs from other countries that charge far less.

"I don't think it's going to be made possible," said Frazier, during an interview on CNBC after an appearance at the conference. "Every time we've tried to do that no FDA commissioner has ever been willing to certify the safety of those drugs."

(Reporting by Ransdell Pierson, Bill Berkrot and Caroline Humer; Editing by Marguerita Choy and Chris Reese)

By Ransdell Pierson and Bill Berkrot

share with twitter share with LinkedIn share with facebook
share via e-mail
12/02 Pharma execs weigh in on possible changes under Trump
11/30 REGENERON PHARMACEUTICALS : Curable working on its biggest genetic sequencing pr..
11/25 REGENERON PHARMACEUTICALS,INC. (NASD : REGN) Files An 8-K Termination of a Mater..
11/25 REGENERON PHARMACEUTICALS INC : Termination of a Material Definitive Agreement (..
11/22 REGENERON PHARMACEUTICALS : and Sanofi to Present Data from Phase 3 Praluent® al..
11/22 REGENERON PHARMACEUTICALS : and Sanofi Announce Praluent® alirocumab Cardiovascu..
11/22 REGENERON PHARMACEUTICALS : Patent Application Titled "Universal Plunger Rods, S..
11/22 REGENERON PHARMACEUTICALS : Curable Initiates the International PSC Genome Proje..
11/22 REGENERON PHARMACEUTICALS : New Type 2 Diabetes Findings Reported from Regeneron..
More news
Sector news : Bio Therapeutic Drugs
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
11/26DJWHAT'S NEWS : Business & Finance -- WSJ
11/26 Johnson & Johnson approaches Actelion about takeover deal
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
12/05 BIOTECH FORUM DAILY DIGEST : Biotech Has Tough Week; Will Conference Buoy Immuno..
12/02 TRUMP AS REAGAN 2.0 - THE ANALOGY IS : What's Next
12/01 Significant Upside Potential For Ophthotech Before Phase 3 Fovista Readout
12/01 ALLERGAN : Low Enough To Like, Or Valeant-Lite?
11/24 TEVA PHARMACEUTICAL : A High-Risk, High-Gain Bet In 2016
Financials ($)
Sales 2016 4 943 M
EBIT 2016 1 849 M
Net income 2016 887 M
Finance 2016 668 M
Yield 2016 -
P/E ratio 2016 48,41
P/E ratio 2017 39,90
EV / Sales 2016 7,76x
EV / Sales 2017 6,60x
Capitalization 39 005 M
More Financials
Duration : Period :
Regeneron Pharmaceuticals  Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Full-screen chart
Technical analysis trends REGENERON PHARMAC...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 451 $
Spread / Average Target 22%
Consensus details
EPS Revisions
More Estimates Revisions
Leonard S. Schleifer President, CEO & Class I Director
P. Roy Vagelos Chairman
Robert E. Landry Chief Financial Officer & Senior VP-Finance
George Damis Yancopoulos Class I Director & Chief Scientific Officer
Charles A. Baker Independent Class III Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN, INC.-11.29%108 084
GILEAD SCIENCES, INC.-28.43%95 331
ACTELION LTD45.20%21 671
More Results